/

China Grants Conditional Approval for 2 Domestically Developed COVID-19 Drugs

31 January 2023
29841
2023-01-31 16:20

China has conducted emergency reviews and granted conditional approval for two homegrown drugs for COVID-19 treatment, the National Medical Products Administration said on Sunday.

One of the newly approved medicines, Xiannuoxin, was jointly developed by Simcere Pharmaceutical Group, headquartered in Nanjing in Jiangsu province, the Shanghai Institute of Materia Medica, the Wuhan Institute of Virology and the Chinese Academy of Medical Sciences. The other new drug, VV116, was jointly developed by Shanghai Vinnerna Biosciences and other research institutes in Shanghai.

This tablet has just been granted conditional approval for COVID-19 treatment. The product code is VV116. Pre-clinical research results show that this drug has significant antiviral effect on the original and variant strains of COVID-19, including Omicron. As of Jan 19, 10 domestically made COVID-19 drugs had either been granted official or conditional market approval or had been authorized to treat viral symptoms, according to the State Council's Joint Prevention and Control Mechanism.

-- End --